Search results for " bone density"

showing 10 items of 19 documents

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Bone damage after chemotherapy for lymphoma: a real-world experience

2021

AbstractBackgroundDespite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among these, a potentially relevant problem is bone loss and the development of fragility fractures.AimTo provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.MethodA cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as comple…

Chemotherapy Osteoporosis Lymphoma Steroids Bone losses OsteoclasticLymphomaBone lossesResearchOsteoclasticDiseases of the musculoskeletal systemVitamin D DeficiencyCross-Sectional StudiesRC925-935RheumatologyBone DensityQuality of LifeBone losses; Chemotherapy; Lymphoma; Osteoclastic; Osteoporosis; Steroids; Aged; Bone Density; Cross-Sectional Studies; Humans; Quality of Life; Lymphoma; Osteoporosis; Vitamin D DeficiencyHumansOsteoporosisChemotherapySteroidsOrthopedics and Sports MedicineAgedBMC Musculoskeletal Disorders
researchProduct

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway

2017

AbstractSkeletal erosion has been found to represent an independent prognostic indicator in patients with advanced stages of chronic lymphocytic leukaemia (CLL). Whether this phenomenon also occurs in early CLL phases and its underlying mechanisms have yet to be fully elucidated. In this study, we prospectively enrolled 36 consecutive treatment-naïve patients to analyse skeletal structure and bone marrow distribution using a computational approach to PET/CT images. This evaluation was combined with the analysis of RANK/RANKL loop activation in the leukemic clone, given recent reports on its role in CLL progression. Bone erosion was particularly evident in long bone shafts, progressively inc…

Male0301 basic medicineChronic lymphocytic leukaemiaClone (cell biology)Osteoclastslcsh:MedicineMice0302 clinical medicineMice Inbred NODBone MarrowPositron Emission Tomography Computed Tomographyhemic and lymphatic diseases80 and overProspective StudiesChroniclcsh:ScienceAged 80 and overSettore ING-IND/24 - Principi Di Ingegneria ChimicaLeukemiaMultidisciplinaryBone Density Conservation AgentsReceptor Activator of Nuclear Factor-kappa BbiologyMiddle AgedLymphocyticLeukemiamedicine.anatomical_structureDenosumabRANKL030220 oncology & carcinogenesisFemaleDenosumabmedicine.drugAdultStromal cellArticle03 medical and health sciencesOsteoclastmedicineAnimalsHumansAgedRANK/RANKL Pathwaybusiness.industryRANK Ligandlcsh:RB-CellDiagnostic markersRANK LigandAdult; Aged; Aged 80 and over; Animals; Bone Density Conservation Agents; Bone Marrow; Denosumab; Female; Glucose; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Mice Inbred NOD; Middle Aged; Osteoclasts; Positron Emission Tomography Computed Tomography; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Xenograft Model Antitumor Assaysmedicine.diseaseLeukemia Lymphocytic Chronic B-CellXenograft Model Antitumor AssaysGlucose030104 developmental biologyChronic Lymphocytic Leukaemiabiology.proteinCancer researchInbred NODlcsh:QBone marrowbusiness
researchProduct

Gray value measurement for the evaluation of local alveolar bone density around impacted maxillary canine teeth using cone beam computed tomography

2021

Background To investigate whether any relationship between local alveolar bone density and maxillary canine impaction using gray values from cone beam computed tomography. Material and Methods The cone beam computed tomography images of 151 patients were retrospectively evaluated. Maxillary canine was defined as an impacted tooth when root formation was complete and the patient’s age older than 13 or the other side of the maxillary canine has completely erupted. Similarly, complete eruption was defined as the tooth in its expected occlusion and position. Using the cone beam computed tomography software, the region of interest which was 5 mm2 in area, was placed in the trabecular bone on cro…

MaleCuspidCone beam computed tomographyBone densitydiagnosisBone DensityOcclusionMaxillaHumansMedicineGeneral DentistryUNESCO:CIENCIAS MÉDICASDental alveolusRetrospective StudiesOrthodonticsOral Medicine and Pathologybusiness.industryImpactionImpacted toothResearchTooth ImpactedMaxillary canineIncreased Bone DensityCone-Beam Computed Tomographynonodontogenic cystsOtorhinolaryngologyFemaleoral cavitySurgeryoral pathologybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis

2016

Background: Serum uric acid (SUA) accounts for about 50% of extracellular antioxidant activity, suggesting that hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis. We aimed to meta-analyse data regarding bone mineral density (BMD), osteoporosis and fractures in people with higher SUA vs. lower SUA concentrations. Materials and methods: Two investigators conducted a literature search using PubMed and Scopus, without language restrictions. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used for BMD; risk ratios (RRs) and adjusted odds ratios (ORs) for cross-sectional data. Most possible adju…

Malemedicine.medical_specialtyBone densityClinical BiochemistryOsteoporosis030209 endocrinology & metabolismBone mineral density; fractures; hyperuricemia; osteoporosis; uric acid; Bone Density; Epidemiologic Methods; Female; Humans; Hyperuricemia; Male; Osteoporosis; Osteoporotic Fractures; Uric AcidhyperuricemiaBiochemistryBone remodelingNO03 medical and health sciences0302 clinical medicineBone mineral density; fractures; hyperuricemia; osteoporosis; uric aciduric acidBone DensityInternal medicinemedicineBone mineral densityHumansHyperuricemiaFemoral neck030203 arthritis & rheumatologyBone mineralbusiness.industryHazard ratioGeneral MedicineOdds ratiofracturesmedicine.diseaseosteoporosismedicine.anatomical_structureEndocrinologyFemalebusinessEpidemiologic MethodsOsteoporotic FracturesBone mineral density fractures hyperuricemia osteoporosis uric acid.
researchProduct

Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate can…

2012

<b><i>Purpose:</i></b> Published data demonstrated that zoledronic acid (ZOL) exhibits antiangiogenetic effects. A promising tool for monitoring antiangiogenic therapies is the measurement of circulating endothelial cells (CECs) and circulating endothelial precursor cells (CEPs) in the peripheral blood of patients. Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer. <b><i>Methods:</i></b> Ten consecutive patients with a histologic diagnosis of low-risk prostate adenocarcinoma were enrolled and received an intravenous infusion of ZOL at baseline (T0), 28 days (T28) and 56 days (T56). Blood samp…

Malemedicine.medical_specialtyPathologyCancer ResearchBone Density Conservation AgentAngiogenesismedicine.medical_treatmentUrologyAngiogenesis InhibitorsAngiogenesis; Circulating endothelial cells; Circulating endothelial precursor cells; Prostate cancer; Zoledronic acid; Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Medicine (all); Oncology; Cancer ResearchFlow cytometryProstate cancerCirculating endothelial cellCell MovementStem CellPrecursor cellMedicineHumansImidazoleNeoadjuvant therapyZoledronic acidAgedEndothelial CellProstate cancermedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryStem CellsMedicine (all)ImidazolesEndothelial CellsProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePeripheral bloodNeoadjuvant TherapyAngiogenesiZoledronic acidDiphosphonateOncologyCirculating endothelial precursor cellProstatic NeoplasmStem cellbusinessmedicine.drugAngiogenesis InhibitorHuman
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

2014

Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endoge…

Oncologymedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismOsteoporosisHypercortisolismAdrenal incidentaloma; Cushing's disease; Glucocorticoids; Osteoporosis; Bone Density Conservation Agents; Cushing Syndrome; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Risk FactorsEndogenyDiseaseadrenal incidentalomaBone remodelingRisk FactorsInternal medicinemedicineHumansCushing SyndromeBone Density Conservation Agentsglucocorticoidsbusiness.industrycushing's diseaseCushing's diseasemedicine.diseaseosteoporosisRheumatologyglucocorticoids; osteoporosis; cushing's disease; adrenal incidentalomaEndocrinologyAdrenal incidentaloma; CUSHING'S DISEASE; Glucocorticoids; OsteoporosisbusinessGlucocorticoidOsteoporotic Fracturesmedicine.drug
researchProduct